A randomized phase II trial of interleukin 2 and interleukin 2-interferon alpha in advanced renal cancer
1998

IL-2 and Interferon Alpha in Advanced Renal Cancer

Sample size: 60 publication Evidence: moderate

Author Information

Author(s): GC Jayson, M Middleton, SM Lee, L Ashcroft, N Thatcher

Primary Institution: CRC Department of Medical Oncology, Christie Hospital, Manchester, UK

Hypothesis

Does the combination of interleukin 2 and interferon alpha provide better efficacy and toxicity outcomes compared to interleukin 2 alone in treating metastatic renal carcinoma?

Conclusion

The combination of IL-2 and interferon alpha is more toxic than IL-2 alone, but both treatments resulted in similar median survival rates.

Supporting Evidence

  • The combination treatment had a higher rate of toxicity compared to IL-2 alone.
  • Both treatment groups had no complete responses, with only two partial responses in the IL-2 group.
  • The median survival was 444 days for IL-2 and 381 days for IL-2/IFN-a.
  • Patients with two or more metastatic sites had lower response rates.

Takeaway

Doctors tested two treatments for kidney cancer, and while one was more toxic, both helped patients live about the same amount of time.

Methodology

Patients were randomized to receive either IL-2 or IL-2 with interferon alpha, and their responses and toxicities were evaluated.

Limitations

The study had a small sample size and included patients with multiple metastatic sites, which may have affected response rates.

Participant Demographics

Patients had a median age of 53 years, with a mix of male and female participants, and all had undergone nephrectomy.

Statistical Information

P-Value

0.98

Statistical Significance

p=0.98

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication